Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

Key Points

Key points are not available for this paper at this time.

Abstract

We developed and validated a novel ECL based sandwich immunoassay for the NfL protein in serum (NfL(Umea47:3)); levels in ALS were more than 20-fold higher than in controls. Our data supports further longitudinal studies of serum NfL in neurodegenerative diseases as a potential biomarker of on-going disease progression, and as a potential surrogate to quantify effects of neuroprotective drugs in clinical trials.

Bookmark

View Full Paper

Cite This Study

Gaiottino et al. (Fri,) studied this question.

synapsesocial.com/papers/69dc253f4ee46a2379b651a7 https://doi.org/https://doi.org/10.1371/journal.pone.0075091

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A comparative study of CSF neurofilament light and heavy chain protein in MS2013 · 156 citations
2A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein2010 · 98 citations
3Toward earlier diagnosis of amyotrophic lateral sclerosis1998 · 89 citations
4Chronic Traumatic Encephalopathy in Blast-Exposed Military Veterans and a Blast Neurotrauma Mouse Model2012 · 968 citations
5Evidence for acute neurotoxicity after chemotherapy2010 · 53 citations

Bookmark

View Full Paper